诺沃·诺迪斯克(Novo Nordisk)的股票在2025年下跌了50 % , 因为Eli Lilly的Zepbound 失去了市场份额, Novo Nordisk's stock fell 50% in 2025 due to lost market share to Eli Lilly’s Zepbound, despite upcoming drug trial catalysts.

诺沃·诺迪斯克(Novo Nordisk)的股票在2025年下跌了近50 % , 市场在减重药物(主要是Eli Lilly的Zepbound)中所占的份额在下降,引发了各种分析家反应。 Novo Nordisk's stock has dropped nearly 50% in 2025 amid declining market share in weight loss drugs, primarily to Eli Lilly’s Zepbound, sparking mixed analyst reactions. 虽然摩根士丹利因美国处方增长疲软而下调了该股的评级，但汇丰银行以管道潜力为由上调了该股的评级。 While Morgan Stanley downgraded the stock due to weak U.S. prescription growth, HSBC upgraded it, citing pipeline potential. 即将发生的主要事件包括林业发展局关于2025年口服Wegovy的决定、1月中旬前CagriSema第3阶段试验结果,以及预计2025年底或2026年初阿尔茨海默氏病试验数据。 Key upcoming events include an FDA decision on an oral Wegovy in 2025, phase 3 trial results for CagriSema by mid-January, and Alzheimer’s trial data expected late 2025 or early 2026. 尽管过去CagriSema数据不足, 阿尔茨海默氏病的试验结果不确定, 这些催化剂可能带来好处。 Despite past underwhelming CagriSema data and uncertain Alzheimer’s trial outcomes, these catalysts may offer upside. 股票交易额大约为56.95美元,仍然低于关键的移动平均数,在1年之间为45.05美元至120.56美元不等。 The stock, trading around $56.95, remains below key moving averages with a 1-year range of $45.05 to $120.56.